Clinicopathological significance of tumor stem cell markers aldh1 and CD133 in colorectal carcinoma by Rezaee, M. et al.
Original Article | Iran J Pathol. 2021; 16(1): 40-50 
Vol.16 No.1 Winter 2021                                                                                   IRANIAN JOURNAL OF PATHOLOGY 
Iranian Journal of Pathology | ISSN: 2345-3656 
Clinicopathological Significance of Tumor Stem Cell Markers ALDH1 and CD133 in 
Colorectal Carcinoma 
 
Maryam Rezaee1# , Elmira Gheytanchi1#, Zahra Madjd 1,2, Mitra Mehrazma1,3* 
 
 
1. Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran 
2. Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran 
3. Department of Pathology, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran 
KEYWORDS  ABSTRACT 
 
ALDH1,  
Cancer Stem Cells,  
CD133, 
Colorectal cancer 
Scan to discover online 
 
 
Background & Objective: Colorectal cancer (CRC) is the third most common cancer 
worldwide with a high mortality rate. The main causes of death in patients are 
recurrence and metastasis which are mainly attributed to the small subpopulation of 
cells within tumors called cancer stem cells (CSCs). This study aimed to evaluate the 
correlation between the expression of ALDH1 and CD133 as CSC associated markers 
and clinicopathological characteristics in CRC. 
Methods: In this cross-sectional study, a total of 483 CRC tumor samples were 
immunohistochemically stained for detection of CD133 and ALDH1 markers. 
Correlations of marker expression with clinicopathological factors were also evaluated. 
Results: There was a significant correlation between the luminal intensity of CD133 
and neural invasion (P=0.05) and between the cytoplasmic intensity of CD133 and 
metastasis (P=0.05). In terms of H-score, a positive significant relation was observed 
between cytoplasmic expression of CD133 and lymph node (P=0.02), neural (P=0.04) 
and vascular invasion (P=0.02). The ALDH1 cytoplasmic expression showed a 
significant correlation with tumor size (P=0.001). 
Conclusion: Our findings showed that increased expression of CD133 and ALDH1 is 
associated with tumor progression and worse outcomes in CRC patients. These markers can 
be good candidates for localized targeting of CSCs using antibodies. Future researches need 
to be improved approaches for early detection of CRC, and treatment monitoring for CRC 
and other cancers. 
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Introduction
Colorectal cancer is one of the third most prevalent 
cancers and the fourth cause of cancer-related mortality 
worldwide with 700,000 deaths annually (1-4). In terms of 
gender, CRC is considered as the second most common 
cancer in females and the third in males (5). The risk factors 
are related to habits or personal characteristics including 
age, history of chronic disease and lifestyle which are 
associated with CRC progression (3). Different mutations 
targeting genes such as tumor suppressors, DNA repairing, 
and oncogenes lead to CRC (6). Based on the gene 
mutation site, CRC could be categorized as sporadic (70%); 
inherited (5%) and familial (25%) (7). The chromosomal 
instability (CIN), microsatellite instability (MSI) and CpG 
island methylator phenotype (CIMP) has been reported as 
being the main mechanisms involved in CRC pathogenesis 
(8). The main pathways such as WNT, TP53, 
MAPK/PI3K, TGF-β, and mutated genes of PTEN, 
PIK3CA, C-MYC, SMAD2, SMAD4, BRAF and KRAS are 
affected by chromosomal changes and translocations (9-
12). Despite the improvement in CRC diagnosis and 
therapy, the survival rate of patients with CRC still remains 
poor because of its drug resistance, metastasis, and 
recurrence (13, 14). Therefore, it is essential to develop and 
implement precise and suitable biomarkers to enhance 
diagnostic processes aiding clinicians in the detection of 
CRC in the earliest stages. Emerging evidence has shown 
that a subpopulation of cells also called tumor initiating or 
cancer stem cells (CSCs) with multi-potency and self-
renewal characteristics have a critical role in CRC 
pathophysiology (15-17). They display chemotherapy 
resistance, differentiation potential, and high 
tumorigenicity and could be a promising therapeutic 
approach for CRC management (18, 19). CSCs has been 
effectively recognized in different solid tumors including 
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CRC (20). Targeting of CSCs could be achieved in CRC 
through the various cell surface markers associated with 
self-renewal, including CD133, CD166, CD44, CD24, 
beta1 integrin-CD29, Lgr5, EpCAM (ESA), ALDH-1, 
Msi-1, DCAMLK1 or EphB receptors (18, 21). Hence, 
understanding which of these markers has the greatest 
effect on a patient’s diagnosis and prognosis has been the 
focus of many studies. The CD133 and ALDH-1 are 
among the main markers that have been linked to CSCs in 
CRC (22). 
The cell surface marker of CD133 also known as 
AC133 in humans or prominin-1 in rodents is a five domain 
transmembrane molecule with a molecular weight of 120 
kDa that has been identified as a normal and putative CSC 
marker in several cancers, including brain tumors, prostate 
carcinoma and CRC (23-29). Previous studies reported the 
in-vitro and in-vivo self-renewal and high tumorigenicity 
potential of CD133 in CRC (28, 30). It has been 
demonstrated that the CD133 expression in combination 
with other putative CSC markers correlated with clinical 
outcomes in CRC patients (31).  
Aldehyde dehydrogenase (ALDH) with several 
isoforms and different cellular functions and tissue 
distribution is located on chromosome 12 (30, 32). It is 
considered as a detoxifying enzyme for oxidation of 
intracellular aldehydes (32, 33). Isoforms of ALDH 
including ALDH-1 may lead to poor prognosis in patients 
and have been reported to be a putative stem cell marker in 
several cancers such as breast cancer (34), pancreatic 
adenocarcinoma (35), ovarian cancer (32) lung cancer and 
colorectal cancer (30, 32, 36). Resistance to chemotherapy 
is attributed to the transcriptional triggering in ALDH1 
leading to drug and radiation resistance in CSCs which was 
first detected in hematopoietic progenitor cells (32). The 
role of ALDH-1 and its isoforms in CSCs characteristics 
including self-renewal, differentiation and epithelial-
mesenchymal transition (EMT) has also been shown in 
xenotransplants of breast cancer and colon cancer (32, 37, 
38). Previous studies in the literature indicated the 
prognostic value of ALDH1 expression in different cancers 
including CRC (39, 40) and some of them showed that 
there was any relation between the ALDH1 expression and 
tumor stage (41).  
Considering the lack of comprehensive information 
focusing on the relationship between concurrent expression 
of putative CSC markers ALDH1 and CD133 with main 
clinicopathological factors in CRC, current study was 
aimed to evaluate the immunohistochemical expression of 
these markers in CRC patients. 
 
    Materials and Methods 
Patient’s Data Collection and Sample Preparation 
In this cross-sectional study, formalin- fixed-paraffin-
embedded (FFPE) tissues from 483 patients, who were 
diagnosed with CRC, were collected from three 
University-based Referral Centers of Hasheminejad, 
Rasoul-Akram and Firoozgar in Tehran, Iran, from 2009 
to 2015. Patients’ medical records were evaluated to 
ensure the following demographic and clinicopathological 
parameters were included, those being ,age, gender, tumor 
size, grade, and stage, tumor location, tumor 
differentiation status, metastasis, lymph node and neural 
tissue invasion. All tumor histology was assessed using 
the hematoxylin and eosin (H&E) stained slides of tumors 
by experienced pathologists. Furthermore, patient data 
was kept confidential and the ethical use of patients’tissue 
samples was approved by the Ethics Committee of the Iran 
University of Medical Sciences (IR.IUMS.REC 
1395.9311100010). 
Construction of Tissue Microarray (TMA) Blocks 
The CRC TMA blocks were prepared as 
aforementioned (40). In brief, the selection of tumor 
representative areas was performed from H&E slides for 
TMA preparation. The cores with a 0.6 mm diameter from 
marked tumor areas were punched into a tissue microarray 
block by Tissue Arrayer Minicore (ALPHELYS, Plaisir, 
France). The TMAs were constructed in five copies for each 
sample, the mean scoring of cores was then considered as 
the final score (27). Finally, the sectioning of TMA blocks 
was performed for immunohistochemical staining . 
Immunohistochemical (IHC) Determination of 
Markers 
The expression level of ALDH1 and CD133 was 
evaluated in CRC sections by the IHC method, as 
described previously (30). In sum, paraffin-embedded 
human CRC TMA blocks were sectioned at 5-μm 
thickness and then mounted onto Super frost slides 
(Superfrost plus, Thermo Scientific, Germany). All slides 
were dewaxed at 60oC for 30 min, deparaffinized with 
xylene and rehydrated in ethylic alcohol serial dilution and 
then treated with 3% hydrogen peroxide for 20 min. For 
antigenic epitope demasking the antigen retrieval process 
was done using pressure-cooking system by submerging 
in citrate buffer (pH: 6.0) as target retrieval solution of 
both markers. After cooling the slides at room 
temperature, they were rinsed in Tris-buffered saline 
(TBS) three times. For primary staining of both markers, 
slides were respectively incubated with rabbit 
recombinant monoclonal ALDH1A1 antibody (1:200, 
overnight at 40oC, ab52492; Abcam; USA) and rabbit 
polyclonal CD133 antibody (1:250, overnight at 40oC, 
ab19898; Abcam; USA). Secondary staining was 
performed using EnVision TM/HRP, Rabbit/Mouse 
reagent (Dako; code K5007; Denmark; Ready to-use) for 
30 min in a wet box at 37oC and then visualized by Dako 
REALTM DAB+ Chromogen (Dako; Denmark) based 
on the manufacturer’s instructions. After washing in 
TBS, slides were finally counterstained with Mayer’s 
hematoxylin dye (Dako; Denmark) for 15 min, and 
dehydrated in ethylic alcohol serial dilution and cleared 
in xylene. 
Immunostaining Evaluation and Scoring System  
Imaging analysis of the CRC TMA cores for ALDH1 
and CD133 expression was performed in a coded manner 
independently by two pathologists (M.M. and M.R.) 
without knowledge about the patients' clinicopathological 
characteristics. Discrepancies between them were 
resolved by consensus. The staining percentage of 
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cytoplasmic and luminal expression of CD133 and 
ALDH1, respectively, scored as follows: 1; less than 25%, 
score 2; 26-50%, score 3; 51-75% and score 4; more than 
75%. The staining intensity was evaluated using a semi-
quantitative system, ranging from non-stained to strong: 0; 
non-staining, 1; weakly staining, 2; moderate staining, 3; 
strong staining. The histochemical score results were 
finally calculated by multiplying the intensity in total 
percentage of positive cells ranging from 0-300 including 
less than 100, between 100-200 and more than 200 . 
Statistical Analysis 
All statistical analyses were performed using SPSS 
version 22 (SPSS Inc., Chicago, IL., USA). Differences in 
ALDH1 and CD133, based on different 
clinicopathological parameters, were estimated by a χ2 
test or Fisher’s exact test, if appropriate. The statistically 
significant difference was considered as P-value<0.05 and 
all statistics are presented to two decimal places. 
 
     Results 
Clinicopathological and Tumor Characteristics of 
Patients 
In the present cross-sectional study, a total of 483 
patients, diagnosed with colorectal adenocarcinoma, 
were included in this study. Out of 483 cases, 52.4% of 
cases were male and 47.6% of them were female with a 
mean age of 59.12±14.8 (range 23-92 years) at the time 
of diagnosis. Of all patients, 46.2% were ≥60 years old 
and 53.8% were <60 years old. The pathological results 
showed that the most prevalent tumor location was 
sigmoid (164 cases, 35.5%), and rectum (129 cases, 
28%). The mean size of tumors was 5 cm, 324 (67.1%) 
tumors were less than 5 cm and 159 (32.9%) were more 
than 5 cm. Tumor cells were classified as well, 
moderately and poorly differentiated. Out of all tumor 
samples, there were 173 (35.8%) well-differentiated, 277 
(57.3%) moderately differentiated and 33 (6.8%) poorly 
differentiated adenocarcinoma cells. Thirty-four (7%) 
patients showed metastasis and 449 (93%) cases had no 
metastasis. Lymph node involvement was present in 181 
patients (37.5%) and absent in 302 patients (62.5%). 
Neural invasion was observed in 97 (20.1%) cases and 
non-invasion in 386 (79.9%) cases and 74 (15.3%) cases 
had vascular invasion. There were 84 (17.4%) TNM 
stage 1, 208 (43.1%) TNM stage 2, 168 (34.8%) TNM 
stage 3 and 23 (4.8%) TNM stage 4 patients. The highest 
prevalence of tumor stage was 2a (38%). 
Correlation Between the Positive Expression of 
CD133 and CRC Clinicopathological Features  
 The CD133 was expressed in cytoplasm of 358 and 
luminal area of 315 tumor samples and intensity of 
staining in CRC tissues are shown in Figure 1. A number 
of tumor samples were excluded from the study due to 
the tissue handling process or lack of tumor within the 
cores. The expression of CD133 varied considerably 
between different tumor samples. In terms of expression 
intensity, strong luminal intensity was observed in 




Fig. 1. Expression patterns of CD133 in CRC tissues. (A) Weak; (B) Moderate; and (C) Strong intensity of staining. 
 
As indicated in Table 1, overall luminal and 
cytoplasmic expression of CD133 was not significantly 
associated with gender, age, tumor size (P>0.05). 66.1% 
of samples which showed neural invasion had high 
expression of CD133. There was significant correlation 
between the luminal intensity of CD133 expression and 
neural invasion (P=0.05). High expression of CD133 
was found in 79.4% of tumor samples with lymph node 
involvement. However, no significant correlation was 
identified between strong luminal and cytoplasmic 
expression of CD133 and lymph node involvement. 40% 
of patients with metastasis showed high cytoplasmic 
expression of CD133 compared to 66.7% of metastatic 
cases with high luminal expression which was 
significant (P=0.05). A higher CD133 luminal intensity 
was detected in 76.4% of moderately or poorly 
differentiated malignant tumor cells compared with the 
well (75%) differentiated tumor cells. These values were 
relatively low in cytoplasmic expression of CD133. 
There was no significant association between luminal 
and cytoplasmic CD133 expression and tumor 
differentiation. 
In terms of CD133 expression H-score as indicated 
in Table 1, 64.6% of male and 69.3% of female cases 
showed high H-score (>200) of luminal CD133 
expression compared to 33.2% male and 26.8% female 
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in cytoplasmic expression of CD133. 64.7. % of cases 
with H-score higher than 200 had tumor size more than 
5cm and 55% of tumors with vascular invasion had 
higher H-score (>200) and 55.4% of tumors with neural 
invasion showed H-score higher than 200. The lymph 
nodes were involved in 73 (68.2%) cases with higher H-
score. There was no significant association between the 
luminal and cytoplasmic H-score of CD133 with age, 
gender, tumor size, and metastasis (P>0.05).  The 
luminal H-score of CD133 presented marked correlation 
with neural invasion (P=0.04). There was a significant 
association between the cytoplasmic H-score of CD133 
with clinical factors including lymph node (P=0.02), 
neural (P=0.04), and vascular (P=0.02) invasion.
 




H-score of CD133 
expression No. (%) 
P-value Intensity of CD133 expression P-value 
Expression 
Pattern 
Low High  Negative Weak Moderate Strong 
 
Cytoplasmic 250(69.8) 108(30.2)  3(0.8) 77(21.5) 125(34.9) 153(42.7)  
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*The values are shown in bold are statistically significant. 
 
Correlation Between the Positive Expression of 
ALDH1 and CRC Clinicopathological Features  
The expression pattern of ALDH1 was mainly 
cytoplasmic in 40% (167/416) of TMA tumors (Figure 2), 
whereas 60% of cases showed negative intensity of 
staining. High ALDH1 expression was distinguished in 
4 (2.7%) of the well-differentiated tumors, 3 (1.3%) of 
moderately differentiated tumors and none of the highly 
expressed tumors showed poorly differentiated pattern. 
Seven cases with metastasis showed high ALDH1 
expression. Only 1.3%, 2.1% and 1.7% of tumors with 
high intensity of staining developed lymph nodes, neural 
and vascular invasion, respectively (Table 2). The 
ALDH1 expression (intensity and H-score) was not 
significantly associated with age, gender, lymph nodes, 
and vascular invasion (P>0.05). Tumors more than 5cm 
in size exhibited H-score higher than 200 in 22.5% of 
cases (Table 2). A considerable positive correlation was 
found between the tumor size and H-score of ALDH1 
expression in tumor cells (P=0.001). A marginal trend 
correlation was also observed between the neural 
invasion and ALDH1 intensity of staining (P=0.07). 
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*The values are shown in bold are statistically significant. 
 
Correlation Between the Expression of 
CD133/ALDH1 and CRC Clinicopathological Features 
The association between immunohistochemical 
CD133 and ALDH1 expression was measured in the 
283 matched cases using Pearson’s chi-square. A 
significant reciprocal relation was found between the 
CD133 and ALDH1 expression (P<0.001). Based on 
the combined analysis, the CD133/ALDH1 expression 
was divided into 4 phenotypes, including CD133-
46 Cancer Stem Cell Markers ALDH1 and CD133 in Colorectal Carcinoma 
Vol.16 No.1 Winter 2021                                                                                     IRANIAN JOURNAL OF PATHOLOGY 
High/ALDH1-High (8.8%) indicating high expression 
of both markers, CD133-Low/ALDH1-Low (8.8%) 
indicating low expression of both markers.CD133-
High/ALDH1-Low (81.3%), and CD133-
Low/ALDH1-High (1.1%). The correlation between 
CD133/ALDH1 phenotypes and clinicopathological 
characteristics of CRC patients was evaluated using the 
one-way ANOVA and Tukey’s post hoc analysis 
(Table 3). A marked positive correlation was only 
observed between the CD133-High/ALDH1-Low 
phenotype and neural invasion representing that this 
phenotype was more dominant in CRC patients 
compared to other phenotypes (P=0.037).
 
Table 3. Correlation between CD133/ALDH1 phenotypes and clinicopathological characteristics in CRC. 
 












































































































































*The values shown in bold are statistically significant 
 
      Discussion 
Colorectal cancer is one of the commonest visceral 
cancers and a leading cause of death throughout the 
world (27). Despite the improving trend of diagnostic 
and therapeutic processes, the majority of CRC patients 
experience a poor prognostic disease which is often 
manifested by drug resistance, recurrence, and 
metastasis (30). It is believed that cancers may be 
gradually organized by their own CSCs as a rare and 
small sub-population of cancer cells with potential to 
cause metastasis and recurrence (42-45). Several 
studies have been performed in this regard to identify 
specific markers for CRC CSCs but there is still 
controversy over the special marker to distinguish a 
distinct CSC population (12, 18, 32, 46). Therefore, 
discovery of more precise CSC markers would be 
helpful in early diagnosis, prognostic classification and 
well-organized targeted therapy of CRC and for 
improving prognosis through the metastasis and local 
recurrence prevention. The current study was carried 
out to assess the expression pattern of CD133 and 
ALDH1 as putative cancer stem cell markers in CRC 
using TMA and IHC techniques among Iranian 
population for the first time. We showed the increased 
expression of CD133 in the majority of CRC tumor 
samples compared to ALDH1. Lymph node, vascular, 
and neural invasion were more common in cases with 
higher CD133 expression than in cases with negative 
or low CD133 expression, which were statistically 
significant (P<0.05). In line with our findings, a meta-
analysis based on the 37 studies reported increased 
CD133 expression in CRC as a poor prognostic factor 
in CRC patients and it was positively correlated with 
lymphatic and vascular invasion, distant metastasis, 
and tumor T category (47). Li and colleagues 
demonstrated that an increased percentage of CD133 
positive tumor cells was linked with poor prognosis in 
CRC patients with higher stage (48). We observed 
CD133 overexpression in CRC cases with advanced 
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stages (III & IV) but differences were not statistically 
significant (P>0.05). In contrast, another study 
reported the correlation between early stage (stage I) 
and worse outcome in CRC patients as a robust 
predictor factor (49). 
Regarding CD133 expression patterns, 
immunohistochemical technique has been applied in 
various studies to show that the CD133 was mainly 
expressed on luminal surface and cell membrane of 
tumors (47-54), while other studies detected that it could 
be expressed both on cytoplasm and membrane of tumor 
cells (44, 55). Differences in the clinicopathological 
significance of tumor stem cell markers including 
CD133 is largely affected by the expression patterns of 
these markers. Epithelial to mesenchymal transition 
(EMT) and finally an invasive and metastatic phenotype 
is considerably linked to the cytoplasmic to membranous 
shift in CD133 localization (49). The CD133 expression 
at luminal surface of CRC tumor glands has been 
reported as an independent predictive marker of CRC 
(55). Our IHC findings revealed that the CD133 was 
mainly located at the luminal surface of most tumor 
samples (66.7% as H-score and 75.9% as intensity of 
staining) which were significantly correlated with CRC 
neural invasion (P<0.05). Kojima et al. reported the 
luminal and cytoplasmic expression of CD133 in 
colorectal cancer mainly in well and moderately 
differentiated tumors but not in the poorly differentiated 
form which is significantly correlated with distant 
metastasis (56). We observed the expression of CD133 
not only in well and moderately differentiated tumors 
but also in poorly differentiated cells that is correlated 
with metastasis (P<0.05). These results are consistent 
with Horst et al.’s study, who found CD133 expression 
at the luminal surface of CRC gland with lumina 
shedding as a predictive marker of poor prognosis (57). 
ALDH1 is a kind of detoxifying enzyme and potential 
CSC markers have been recognized in different cancers 
including head and neck (30)  and breast (58) and several 
studies has focused on its prognostic significance in 
different cancers (30). An increase in cell proliferation and 
invasion capacity has been attributed to the role of 
ALDH1 in CSC characteristics and in the biological 
features of tumors (58, 59). Zhou and colleagues have 
demonstrated the relation between high expression of 
ALDH1 and poor outcome in CRC patients but it was not 
correlated to Lymph node invasion compared to CD133 
(59). Lugli et al. reported no correlation between the 
ALDH1 expression and survival (59). They detected high 
ALDH1 expression in only 23.3% of CRC cases without 
any differences in survival rate (30). Although a large 
number of studies have investigated the role of ALDH1 
expression on CRC patient’s outcomes, controversy 
regarding prognostic significance of ALDH1 still 
remains. Therefore, further research should be conducted 
to reach a definite conclusion. Our study indicated that the 
ALDH1 CSC marker was only overexpressed in 40% of 
CRC patients which are partly consistent with the findings 
of the Lugli study (60). Further significant findings of the 
present study was that well and moderately differentiated 
tumors had smaller tumor size and exhibited a lower 
expression of ALDH1 in terms of H-score compared with 
poorly differentiated tumors which was statistically 
significant (P=0.001). Meanwhile, a meta-analysis study on 
the prognostic value of ALDH1, as a cancer stem cell 
marker indicated that ALDH1 was expressed in different 
levels among various populations of CRC patients (18). 
Nevertheless, differences between expression degrees of 
CSC markers and their complicated mechanisms are not yet 
clear. Liu et al. (2014) supposed that there were differences 
in expression patterns of ALDH1 and its prognostic 
significance between western and eastern people (61). 
Chen and colleagues systematically reviewed a large 
population of patients from western and eastern countries 
and concluded that the expression rate of ALDH1 is higher 
among the western populations (52%) compared to low rate 
expression among the eastern populations (39%).  
Since CRC cells expressing one of putative CSC 
markers displayed high tumorigenicity especially in 
combination with other CSC markers (62), the 
assessment of combined markers may be helpful in 
better understanding tumor characteristics than those 
considered individually. Co-expression of CD133 and 
ALDH1 has been seen in a wide range of tumor cells, 
including lung (61) and gastric cancers which are 
involved in tumor invasion, metastasis and poor 
prognosis of patients (62). Therefore, we assessed the 
prognostic significance of combined CD133/ALDH1 
phenotypes with clinicopathological factors in CRC. 
Our analysis revealed that CD133High/ALDH1Low 
phenotype was more frequent in CRC tumors than 
other combined phenotypes. There was also a positive 
significant correlation between this phenotype with 
neural invasion of tumors. Considering the different 
degree of CSC markers expression in several 
malignancies and differences among the various 
populations and markers localization, it can be 
concluded that CD133High/ALDH1Low phenotype 




Combined detection of CD133 and ALDH1, as 
CSC associated markers, is likely to be valuable in 
understanding their clinicopathological and prognostic 
significance in CRC.  Furthermore, patient 
classification in combined expression phenotypes of 
putative CSC markers could be identified as 
appropriate targeted therapies according to different 
subgroups of CRC patients and thus management of 
tumor progression, especially in advanced cases. 
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